As ITGA4 can be targeted with monoclonal antibodies such as natalizumab, and VLA‐4‐specific inhibitors such as BIO1211 and BIO5192, these findings suggest that ITGA4 may be a potential therapeutic target in GIST. Here, ITGA4 is linked to gastrointestinal stromal tumor.